Kasinski A L, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader A G, Slack F J
1] Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA [2] Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Mirna Therapeutics, Inc., Austin, TX, USA.
Oncogene. 2015 Jul;34(27):3547-55. doi: 10.1038/onc.2014.282. Epub 2014 Sep 1.
Targeted cancer therapies, although often effective, have limited utility owing to preexisting primary or acquired secondary resistance. Consequently, agents are sometimes used in combination to simultaneously affect multiple targets. MicroRNA mimics are excellent therapeutic candidates because of their ability to repress multiple oncogenic pathways at once. Here we treated the aggressive Kras;p53 non-small cell lung cancer mouse model and demonstrated efficacy with a combination of two tumor-suppressive microRNAs (miRNAs). Systemic nanodelivery of miR-34 and let-7 suppressed tumor growth leading to survival advantage. This combinatorial miRNA therapeutic approach engages numerous components of tumor cell-addictive pathways and highlights the ability to deliver multiple miRNAs in a safe and effective manner to target lung tissue.
靶向癌症疗法虽然通常有效,但由于存在原发性或获得性继发性耐药,其效用有限。因此,有时会联合使用药物来同时影响多个靶点。微小RNA模拟物是优秀的治疗候选物,因为它们能够同时抑制多个致癌途径。在这里,我们对侵袭性Kras;p53非小细胞肺癌小鼠模型进行了治疗,并证明了两种肿瘤抑制性微小RNA(miRNA)联合使用的疗效。miR-34和let-7的全身纳米递送抑制了肿瘤生长,带来了生存优势。这种联合miRNA治疗方法涉及肿瘤细胞成瘾途径的众多组成部分,并突出了以安全有效的方式递送多种miRNA以靶向肺组织的能力。